Home/Biosimilar Atlas/Rituximab/Biocad rituximab

Biocad rituximab

Rituximab biosimilar developed by Biocad, development code BCD-020. Reference product MabThera (Rituxan in the United States).

Brands by market: Brand not published by CDSCO (India, import) · Commercial partner or holder: Biocad India (import) · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOJul 2017permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
RituximabmoleculeBiocaddeveloper1 of 7markets2trials behind it2other products, same developer6rival developers in its markets

About Biocad rituximab

Biocad, the Russian developer, has held an Indian import permission for its rituximab since 2017, covering lymphoma, leukaemia and rheumatoid arthritis. It is one of three Biocad antibodies imported into India.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Biocad India Pvt Ltd
Pathway
Import and marketing permission
Approved
Jul 2017
Application or permission
Import permission
Indications as licensed
NHL, RA, CLL, GPA and MPA
Presentations
100 mg and 500 mg vials
Source
S013 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Trials behind this product

Comparative trials on ClinicalTrials.gov matched to Biocad rituximab by development code, brand or developer. Registry data, sponsor-entered.

CandidateDeveloper or sponsorReference productPhaseDesignRegistry statusStartedPrimary completionRegistry record
BCD-020BiocadMabTheraPhase 3Comparative efficacyCompletedDec 2012Jul 2015NCT01759030
BCD-020BiocadMabTheraPhase 3Comparative efficacyCompletedSep 2011Jan 2017NCT01701232

Other developers in the same markets

Where Biocad rituximab holds an approval, these are the other rituximab biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO6Hetero (Hetero rituximab), Intas Pharmaceuticals (Intas rituximab), Reliance Life Sciences (Reliance Life Sciences rituximab), Virchow Biotech (Virchow Biotech rituximab), Zenotech Laboratories (Zenotech rituximab), Zydus Lifesciences (Zydus rituximab)

Same developer, other molecules

Other biosimilars in the Atlas developed by Biocad: Biocad infliximab, Biocad trastuzumab.

Chronology

Sources

All rituximab biosimilars

Planning rituximab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.